-+ 0.00%
-+ 0.00%
-+ 0.00%

Sionna Therapeutics Presents SION-719 And SION-451 Phase 1 Data, And New Preclinical Data Showing NBD1 Stabilizer Impact On F508del-CFTR Half-Life, At NACFC 2025

Benzinga·10/24/2025 17:21:54
Listen to the news

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets

New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington October 22-25.